Piper Jaffray Upgrades DaVita Inc. (DVA) to Buy; Expect Strong Q1 Results
More News related to DVA
- Local Elected Officials, Community Leaders Join DaVita, Industrial Bank for Operation: Happy Thanksgiving
- DaVita Kidney Awareness Run/Walk Series Raises More Than $250,000 in the Fight Against Chronic Kidney Disease
- DaVita Appoints Scott Drake as Senior Vice President
- DaVita's 43 Abstracts Highlight Commitment to Quality Care at American Society of Nephrology's 2009 Renal Week
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
Piper Jaffray upgrades DaVita Inc. (NYSE: DVA) from Neutral to Buy. Price target $57.
Piper analyst says, "We believe the sell-off and continued weakness in shares of DVA since the release of the Obama budget and health care reform proposal in late February to be vastly overdone, and feel recent analyses that focus solely on one aspect of the reform proposal (i.e., the possible introduction of a low-cost public health plan to compete with commercial insurers) in isolation, without balancing the practical realities of how other payers and providers will change their policies as a result, is both misguided and dangerous. Additionally, we note that the current health care proposal is just that, a proposal, with very few details and an extremely difficult path ahead before it could become a reality."
To see more analyst ratings on DVA Click Here.
DaVita Inc. is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD).
Related Categories
UpgradesStocks Mentioned
+0.68Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
